PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

被引：13
|
作者：
Cainzos-Achirica, Miguel [1 ]
Martin, Seth S. [1 ]
Cornell, John E.
Murow, Cynthia D.
Guallar, Eliseo
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 01期
关键词：
HYPERCHOLESTEROLEMIA; LDL;
D O I：
10.7326/M15-0920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [41] Cholesterol Management in the Era of PCSK9 Inhibitors
    Svatikova, Anna
    Kopecky, Stephen L.
    CURRENT CARDIOLOGY REPORTS, 2017, 19 (09)
  • [42] Cholesterol Management in the Era of PCSK9 Inhibitors
    Anna Svatikova
    Stephen L. Kopecky
    Current Cardiology Reports, 2017, 19
  • [43] PCSK9 inhibitors- A new age in lipid management?
    Grant, Peter J.
    DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (03): : 171 - 171
  • [44] PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
    Perrone-Filardi, P.
    Basile, C.
    Asile, G.
    Abbate, C.
    Catalano, A.
    Merlini, P. A.
    Calabro', P.
    Iannuzzo, G.
    Ciccone, M. M.
    Paloscia, L.
    Varbella, F.
    Brunetti, N. D.
    Indolfi, C.
    Paolillo, S.
    Gargiulo, P.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2378 - 2378
  • [45] Lipid Lowering Therapy and Circulating PCSK9 Concentration
    Nozue, Tsuyoshi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (09) : 895 - 907
  • [46] Lipid-Lowering Agents: Targets Beyond PCSK9 (vol 124, pg 386, 2019)
    Hegele
    CIRCULATION RESEARCH, 2020, 127 (10) : E251 - E251
  • [47] Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
    Khoshnejad, Makan
    Patel, Ami
    Wojtak, Krzysztof
    Kudchodkar, Sagar B.
    Humeau, Laurent
    Lyssenko, Nicholas N.
    Rader, Daniel J.
    Muthumani, Kar
    Weiner, David B.
    MOLECULAR THERAPY, 2019, 27 (01) : 188 - 199
  • [48] Engineering of DNA-Encoded PCSK9 Monoclonal Antibodies as Novel Lipid-Lowering Therapeutics
    Khoshnejad, Makan
    Patel, Ami
    Kudchodkar, Sagar
    Wojtak, Krzysztof
    Muthumani, Kar
    Weiner, David B.
    MOLECULAR THERAPY, 2018, 26 (05) : 282 - 282
  • [49] PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
    Chapman, M. John
    Stock, Jane K.
    Ginsberg, Henry N.
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (06) : 511 - 520
  • [50] Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9): A new approach in lipid lowering treatment
    Klouras, E.
    Liberopoulos, E.
    Elisaf, M.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (01): : 77 - 84
12345